Clinical Trial Update: Assessment of Efficacy of Mirabegron, a New beta3-adrenergic Receptor in the Prevention of Heart Failure [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the efficacy of mirabegron for prevention of heart failure in the context of left ventricular hypertrophy; the study has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure
• Left Ventricular Hypertrophy

Drugs mentioned

• Mirabegron (mirabegron)

Snippet

Sponsor: Jean-Luc Balligand | Conditions: Hypertrophy, Left Ventricular | Phase 2 | Status: COMPLETED